APM2 is a novel mediator of cisplatin resistance in a variety of cancer cell types regardless of p53 or MMR status

International Journal of Cancer

Volumn 125, Issue 5, 2009, Pages 1193-1204

  Scott, Bradley J ^a,b   Qutob, Sami ^c   Liu, Qing Y ^d   Ng, Cheng E ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c HEALTH CANADA   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

APM2; C10orf116; Cisplatin; Microarray; Resistance; siRNA

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; ETOPOSIDE; MESSENGER RNA; PROTEIN P53; SHORT HAIRPIN RNA; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APM2 GENE; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN HCT116; CELL STRAIN MCF 7; CELL TYPE; CHROMOSOMAL LOCALIZATION; CHROMOSOME 10; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; OPEN READING FRAME; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; X IRRADIATION;

ADIPONECTIN; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; COLONY-FORMING UNITS ASSAY; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650076387     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24465     Document Type: Article

References (74)

1. Prestayko AW, D'Aoust JC, Issell BF, Crooke ST. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 1979;6:17-39.
2. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003;146:1-54.
3. Ozols RF. Ovarian cancer: new clinical approaches. Cancer Treat Rev 1991;18 (Suppl A):77-83.
4. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
5. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes-a review. Anticancer Drugs 2000;11: 225-36.
6. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Jr, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
7. Segal-Bendirdjian E, Mannone L, Jacquemin-Sablon A. Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin- resistance. Cell Death Differ 1998;5:390-400.
8. Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 2006;5:1239-47.
9. Fan S, Smith ML, Rivet DJ, II, Duba D, Zhan Q, Kohn KW, Fornace AJ, Jr, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55:1649-54.
10. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56:892-8.
11. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58:3579-85.
12. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis Protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003;63: 7081-8.
13. Whiteside MA, Chen DT, Desmond RA, Abdulkadir SA, Johanning GL. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 2004;23:744-52.
14. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, Ochiai K, Tanaka T, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001;14:305-15.
15. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004; 10:272-84.
16. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS, Chun JH, Kim IH, Kim IJ, Kang HC, Park JH, Bae JM, et al. DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 2004;316:781-9.
17. Prasad NB, Biankin AV, Fukushima N, Maitra A, Dhara S, Elkahloun AG, Hruban RH, Goggins M, Leach SD. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005;65: 1619-26.
18. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-9.
19. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
20. Onda M, Emi M, Nagai H, Nagahata T, Tsumagari K, Fujimoto T, Akiyama F, Sakamoto G, Makita M, Kasumi F, Miki Y, Tanaka T, et al. Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers. J Cancer Res Clin Oncol 2004; 130:537-45.
21. Qutob SS, Multani AS, Pathak S, Feng Y, Kendal WS, Ng CE. Comparison of the X-radiation, drug and ultraviolet-radiation responses of clones isolated from a human colorectal tumor cell line. Radiat Res 2004;161:326-34.
22. Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 Cells. Cancer Res 2003;63:6935-41.
23. Lin X, Ramamurthi K, Mishima M, Kondo A, Howell SB. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Mol Pharmacol 2000;58: 1222-29.
24. Vegesna R, Ch S, Ghanshyam S. Induction of p53 dependent apoptosis upon overexpression of a nuclear protein tyrosine phosphatase. FEBS lett 1999;453:308-12.
25. Flanagan SA, Krokosky CM, Mannava S, Nikiforov MA, Shewach DS. MLH1 deficiency enhances radiosensitization with 5-Fluorodeoxyuridine by increasing DNA mismatches. Mol Pharmacol 2008;74: 863-71.
26. Schwarz VA, Hornung R, Fedier A, Fehr MK, Walt H, Haller U, Fink D. Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells. Br J Cancer 2002;86:1130-35.
27. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK, Schweinfest CW. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001;61:4112-21.
28. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003;100:11636-41.
29. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56: 3087-90.
30. Ng CE, Liu QY, Qutob SS, Scott BJ, Tan WL, Mesak FM. Transcriptomic profiling of radiation-resistant or -sensitive human colorectal cancer cells: acute effects of a single X-radiation dose. Int J Oncol 2007;30:1369-80.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. 1995;B:289-300.
32. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 1998;58:698-703.
33. Chung YM, Kim B-G, Park C-S, Huh SJ, Kim J, Kuk J, Mi Ps, Soo CB, Suk KJ, Do KY, Bae YD-S. Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer 2005;117:194-201.
34. Gosepath EM, Eckstein N, Hamacher A, Servan K, von Jonquieres G, Lage H, Gyorffy B, Royer HD, Kassack MU. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer 2008;123:2013-19.
35. Sherman ML, Datta R, Hallahan DE, Weichselbaum RR, Kufe DW. Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA 1990;87:5663-6.
36. Yamaguchi K, Ishikawa T, Kondo Y, Fujisawa M. Cisplatin regulates sertoli cell expression of transferrin and interleukins. Mol Cell Endocrinol 2008;283:68-75.
37. DeHaan RD, Yazlovitskaya EM, Persons DL. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol 2001;48:383-8.
38. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005;41:2449-61.
39. Marij JP, Welters MJ, Fichtinger-Schepman AM, Baan RA, Hermsen MA, van der Vijgh WJ, Cloos J, Braakhuis BJ. Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer 1997;71:410-5.
40. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984;100: 19-24.
41. Schilder RJ, Ozols RF. New therapies for ovarian cancer. Cancer Invest 1992;10:307-15.
42. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83.
43. Okuda K, Usui E, Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J Lipid Res 1995;36:1641-52.
44. Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther 2008;7:3047-55.
45. Qutob SS, Proulx D, Mesak FM, Ng CE. Effects of N1. N13- diethylnorspermine (DENSPM) and. X-radiation treatment on human colorectal tumor clones with varying X-radiation and drug responses. Radiat Res 2005;163:357-63.
46. Fogel-Petrovic M, Vujcic S, Brown PJ, Haddox MK, Porter CW. Effects of polyamines, polyamine analogs, and inhibitors of protein synthesis on spermidine-spermine N1-Acetyltransferase gene expression. Biochemistry 1996;35:14436-44.
47. Snyder RD, Schroeder KK. Radiosensitivity of polyamine-depleted HeLa cells and modulation by the aminothiol WR-1065. Radiat Res 1994;137:67-75.
48. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58.
49. Marverti G, Monti MG, Pegg AE, McCloskey DE, Bettuzzi S, Ligabue A, Caporali A, D'Arca D, Moruzzi MS. Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin. Carcinogenesis 2005;26:1677-86.
50. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, Lage H. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-712.
51. Graham J, Muhsin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov 2004;3:11-12.
52. Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, Zelcer S, Silva M, Odame I, Mpofu C, Strother D, Bouffet E. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a canadian pediatric brain tumor consortium experience. Cancer 2008;112:892-9.
53. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-65.
54. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
55. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK. Cisplatin induces p53-dependent Flice-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 2008;68:4511-7.
56. Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 2006;102:348-55.
57. Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008;122:534-46.
58. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-44.
59. Martin LP, Hamilton TC, Schilder RJ. Platinum Resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5.
60. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000;6:1415-21.
61. Nguyen KH, Hachem P, Khor LY, Salem N, Hunt KK, Calkins PR, Pollack A. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Int J Radiat Oncol Biol Phys 2005;63:238-46.
62. Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 1990;2: 93-100.
63. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
64. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
65. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 2000;46: 255-62.
66. Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Cell Growth Differ 1999; 10:473-8.
67. Ikeda Y, Taira K. Ligand-targeted delivery of therapeutic siRNA. Pharm Res 2006;23:1631-40.
68. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25:1149-57.
69. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 22:5712-5.
70. Shen C, Buck AK, Liu X, Winkler M, Reske SN. Gene silencing by adenovirus-delivered siRNA. FEBS Lett 2003;539:111-4.
71. Zhao L-J, Jian H, Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene 2003;316:137-41.
72. Sun L, Gao H, Sarma VJ, Guo RF, Ward PA. Adenovirus-mediated in vivo silencing of anaphylatoxin receptor C5aR. J Biomed Biotechnol 2006;2006:28945.
73. Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X. Oncolytic adenovirus-mediated shRNA against apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther 2008;15:484-94.
74. Xiang DB, Chen ZT, Wang D, Li MX, Xie JY, Zhang YS, Qing Y, Li ZP, Xie J. Chimeric adenoviral vector Ad5//F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther 2008;15:625